{"product_id":"nmtc-marketing-mix","title":"(NMTC) NeuroOne Medical Technologies Corporation Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis NeuroOne Medical Technologies Corporation 4P's Marketing Mix Analysis explains the company’s product (neurostimulation and neural interfacing devices), how they’re used in neuromodulation and surgical settings, and what’s shown on this page: a real preview\/sample of the analysis. Purchase the full version to get the complete, ready-to-use 4P report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThin-film electrode platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeuroOne Medical Technologies Corporation’s core product is a thin-film electrode platform built for neurophysiology, not general medical use. It supports two key workflows: diagnostic recording and therapeutic treatment. In fiscal 2025, this focused design matters because it targets high-value neurology procedures where precision and signal quality drive adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ecEEG monitoring electrodes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeuroOne Medical Technologies Corporation’s cEEG monitoring electrodes target continuous electroencephalogram monitoring, which can track brain activity for 24 hours or longer in ICU and other high-acuity settings. This product supports neurological evaluation by giving clinicians a clearer view of seizures and other abnormal patterns over time. In 2025, NeuroOne was still a small-cap medtech with limited revenue, so every new clinical placement matters for scale and adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003esEEG monitoring electrodes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeuroOne Medical Technologies Corporation’s sEEG monitoring electrodes target invasive brain monitoring for epilepsy and related neurosurgical care. They help physicians localize seizure onset and other neural signals, a need tied to the roughly 50 million people living with epilepsy worldwide. In the 4P mix, this is a focused product for high-acuity procedures where precision can drive surgical planning and treatment choices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRF ablation generator\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeuroOne Medical Technologies Corporation and RBC Medical Innovations are developing an RF ablation generator for use with NeuroOne’s proprietary electrode platform. In Product terms, it adds a targeted brain tissue ablation tool to the company’s neurology stack, aimed at tighter control and better procedural precision.\u003c\/p\u003e\n\u003cp\u003eThe platform is still a development asset, so its near-term value is tied to design progress, regulatory clearance, and future hospital adoption.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePaired with proprietary electrodes\u003c\/li\u003e\n\u003cli\u003eTargets controlled brain ablation\u003c\/li\u003e\n\u003cli\u003eSupports NeuroOne’s neurology line\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDual-function monitor-and-ablate system\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeuroOne Medical Technologies Corporation’s dual-function monitor-and-ablate electrode combines signal recording and tissue ablation in one platform, which can cut tool swaps in some neurosurgical cases. That matters in precision procedures where speed, targeting, and workflow control are critical. In the 4P mix, it supports a premium product position built around fewer steps and tighter procedural control.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecords and ablates with one device\u003c\/li\u003e\n\u003cli\u003eCan reduce separate tool use\u003c\/li\u003e\n\u003cli\u003eTargets precision neurosurgery\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeuroOne’s Focused Neurology Portfolio Targets Precision Brain Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNeuroOne Medical Technologies Corporation’s Product mix centers on thin-film neurology devices: cEEG electrodes, sEEG electrodes, and a dual-function monitor-and-ablate platform. In fiscal 2025, that narrow focus fit high-acuity brain care, where precision and workflow speed matter most.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ecEEG\u003c\/td\u003e\n\u003ctd\u003e24h+ brain monitoring\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003esEEG\u003c\/td\u003e\n\u003ctd\u003eEpilepsy localization\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDual platform\u003c\/td\u003e\n\u003ctd\u003eRecord and ablate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eDelivers a concise, company-specific breakdown of NeuroOne Medical Technologies Corporation’s Product, Price, Place, and Promotion strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eTurns NeuroOne’s 4Ps into a quick, clear snapshot that relieves analysis overload and speeds decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable list of industry reports, clinical data, and regulatory sources to speed due diligence and validate NeuroOne’s market, pricing, and competitive claims.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEden Prairie, Minnesota HQ\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeuroOne Medical Technologies Corporation is headquartered in Eden Prairie, Minnesota, which anchors corporate operations and management. The site also places Company Name in a strong U.S. medical device hub, close to talent, suppliers, and industry partners. That local base supports faster coordination for product, regulatory, and commercial work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnited States clinical market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeuroOne Medical Technologies Corporation’s place strategy is centered on U.S. healthcare buyers, and the U.S. has about 6,120 hospitals to target. Its devices fit regulated hospital and procedural settings, so adoption depends on clinician trust, evidence, and purchasing approvals. In this market, sales follow hospital procurement cycles and physician use, not retail demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital procurement channel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeuroOne Medical Technologies Corporation sells through the hospital procurement channel, so the main buyers are hospitals and specialty medical centers, not retail patients. These purchases move through formal buying steps, such as clinical review, purchasing approval, and contract checks, which makes distribution institutional. That setup fits a B2B model and can lengthen sales cycles, but it also supports larger order values and repeat account-based sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEpilepsy and neurosurgery centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEpilepsy and neurosurgery centers are the right placement for NeuroOne Medical Technologies Corporation because they run cEEG and sEEG workflows that need precise monitoring and ablation tools. About 50 million people live with epilepsy worldwide, and roughly 30% have drug-resistant seizures, which keeps these centers in steady demand for advanced procedures.\u003c\/p\u003e\n\u003cp\u003ePlacement should follow neurologists and neurosurgeons, since they decide when to monitor, localize, and ablate. That makes NeuroOne Medical Technologies Corporation a workflow fit for centers that need tools built for both diagnosis and surgery.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets cEEG and sEEG sites\u003c\/li\u003e\n\u003cli\u003eFits drug-resistant epilepsy care\u003c\/li\u003e\n\u003cli\u003eSupports neurologist-led workflows\u003c\/li\u003e\n\u003cli\u003eNeeds specialized monitoring and ablation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDirect physician engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDirect physician engagement is central to NeuroOne Medical Technologies Corporation’s placement strategy because market access depends on trust with surgeons, neurologists, and care teams. Field reps must train users, support evaluations, and help with procedures, so selling is done case by case, not just through distributors. That makes clinical education a direct driver of adoption.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTraining speeds physician adoption.\u003c\/li\u003e\n\u003cli\u003eProcedural support reduces trial friction.\u003c\/li\u003e\n\u003cli\u003eField selling improves placement access.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeuroOne Targets U.S. Hospitals for Clinician-Led Adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNeuroOne Medical Technologies Corporation’s place strategy is U.S.-hospital based, with about 6,120 hospitals as the main buying pool. Its devices are placed in epilepsy and neurosurgery centers where cEEG and sEEG workflows need clinician-led, regulated use.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePlace factor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. hospitals\u003c\/td\u003e\n\u003ctd\u003eAbout 6,120\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEpilepsy burden\u003c\/td\u003e\n\u003ctd\u003e50 million worldwide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDrug-resistant seizures\u003c\/td\u003e\n\u003ctd\u003eRoughly 30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThat makes direct physician engagement and case-by-case hospital selling central to adoption.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eNeuroOne Medical Technologies Corporation Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual NeuroOne Medical Technologies Corporation 4P's Marketing Mix analysis you’ll receive instantly after purchase—fully complete and ready to use, with product, price, place, and promotion evaluated for strategic clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA clearance milestones\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFDA clearance is a strong promo hook for NeuroOne Medical Technologies Corporation because a 510(k) win tells hospitals the device has met a clear legal and clinical bar. NeuroOne can point to its FDA 510(k) clearances, including OneRF Ablation System clearance in 2024, to reduce buyer risk and support purchasing decisions. In medtech, that kind of milestone often matters more than claims, because it can shorten adoption cycles and build trust with clinicians and buyers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical evidence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical evidence is central to NeuroOne Medical Technologies Corporation’s promotion because it supports adoption in neurology and neurosurgery, where physicians want proof of safety and performance. Real-world use data helps validate device results after launch and strengthens purchasing decisions.\u003c\/p\u003e\n\u003cp\u003eFor a company with limited scale, evidence carries more weight than broad brand spend. It helps educate physicians, supports hospital reviews, and can speed conversion in a market where clinical credibility drives demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific conference presence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eScientific conference presence lets NeuroOne Medical Technologies Corporation reach thousands of neurologists and neurosurgeons at one time; major events like the American Academy of Neurology meeting draw over 10,000 attendees. In this niche market, live demos help show product features and the full procedure workflow in a way papers and ads cannot. It also supports trust and faster adoption in a field where buying choices are specialist-led.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnership announcements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeuroOne Medical Technologies Corporation uses the RBC Medical Innovations collaboration as a live promotion signal: it shows active radio frequency ablation development, not just slideware. One named partnership can lift trust fast, especially for a small medtech company, because it links NeuroOne Medical Technologies Corporation to an outside technical team and real product work.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRBC Medical Innovations adds credibility\u003c\/li\u003e\n\u003cli\u003eSupports radio frequency ablation development\u003c\/li\u003e\n\u003cli\u003eSignals active product progress\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePress releases and investor communications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePress releases and investor updates let NeuroOne Medical Technologies Corporation show progress fast, which matters for a small-cap medtech name that still needs trust from buyers, channel partners, and capital markets. In 2025, the company reported 9M revenue of $0.9 million and a net loss of $5.6 million, so clear news flow helps frame milestones, not just financial noise.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBuilds trust with investors\u003c\/li\u003e\n\u003cli\u003eRaises awareness with partners\u003c\/li\u003e\n\u003cli\u003eSupports small-cap credibility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeuroOne Sells Trust, Not Ad Spend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePromotion for NeuroOne Medical Technologies Corporation leans on proof, not broad ad spend: FDA 510(k) clearances, clinical data, conference demos, and partner news all reduce buyer risk. That matters for a small medtech company with 9M 2025 revenue of $0.9 million and a net loss of $5.6 million, because trust has to do the heavy lifting.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOneRF clearance\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003eRegulatory trust\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e9M revenue\u003c\/td\u003e\n\u003ctd\u003e$0.9M\u003c\/td\u003e\n\u003ctd\u003eNews flow context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet loss\u003c\/td\u003e\n\u003ctd\u003e$5.6M\u003c\/td\u003e\n\u003ctd\u003eCredibility gap\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAAN attendance\u003c\/td\u003e\n\u003ctd\u003e10,000+\u003c\/td\u003e\n\u003ctd\u003ePhysician reach\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo public list price\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeuroOne Medical Technologies Corporation does not publicly disclose a standard list price, so buyers do not see a fixed sticker price. In hospital-based medtech, pricing is usually negotiated case by case with health systems and purchasing groups, not posted online. That gives the company flexibility to tailor terms by order size, procedure mix, and customer contract.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional contract pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeuroOne Medical Technologies Corporation sells to hospitals and procedural centers, so price is set in account-level contracts, not at a shelf tag. Procurement teams drive the deal, with volume commits, trial terms, and reimbursement fit shaping the final net price. That makes pricing less about one list price and more about winning each center’s buying process.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePremium value-based positioning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeuroOne Medical Technologies Corporation can justify premium, value-based pricing because its products support complex neurological procedures where buyers care most about outcomes, workflow, and safety. In FY2025, that means price is judged against clinical value, not just unit cost, so hospitals will pay more when the tech helps reduce risk and improve procedure efficiency.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCapital plus consumable model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeuroOne Medical Technologies Corporation uses a capital plus consumable model: the RF generator is sold as upfront equipment, while electrodes drive recurring per-case revenue. That split is standard in medtech because it lowers the initial barrier for hospitals and can lift lifetime value as procedure volumes grow. In 2025, this kind of model mattered even more as U.S. hospital capital budgets stayed tight and recurring-use pricing carried better visibility.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRF generator: capital sale\u003c\/li\u003e\n\u003cli\u003eElectrodes: recurring procedural use\u003c\/li\u003e\n\u003cli\u003eTwo pricing streams, one customer\u003c\/li\u003e\n\u003cli\u003eBuilt for repeat-case revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eReimbursement-sensitive economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeuroOne Medical Technologies Corporation’s pricing has to fit hospital reimbursement and case economics, because purchase decisions are tied to whether epilepsy, pain, and neurosurgery cases clear DRG and APC payment limits. In U.S. hospital care, reimbursement is often bundled, so device price must leave room for labor, imaging, OR time, and margin.\u003c\/p\u003e\n\u003cp\u003eThat means value proof matters more than list price: if a device shortens procedure time or supports an extra billable case, it is easier to adopt. Pricing should match payer and provider realities, not just product features.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBundle-friendly pricing wins adoption\u003c\/li\u003e\n\u003cli\u003eCase time savings support ROI\u003c\/li\u003e\n\u003cli\u003eReimbursement drives hospital buying\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNegotiated Pricing Drives Recurring Sales for NeuroOne\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNeuroOne Medical Technologies Corporation’s price is negotiated, not posted, so hospitals buy on contract terms tied to volume, reimbursement, and workflow value. FY2025 pricing is split between the RF generator as upfront capital and electrodes as recurring per-case revenue, which supports repeat sales and lowers the first buy-in for hospital customers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePrice point\u003c\/th\u003e\n\u003cth\u003eFY2025 takeaway\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eList price\u003c\/td\u003e\n\u003ctd\u003eNot publicly disclosed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRF generator\u003c\/td\u003e\n\u003ctd\u003eUpfront capital sale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eElectrodes\u003c\/td\u003e\n\u003ctd\u003eRecurring procedural revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBuyer focus\u003c\/td\u003e\n\u003ctd\u003eROI and reimbursement fit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234711413001,"sku":"nmtc-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/nmtc-marketing-mix.webp?v=1785726459","url":"https:\/\/dcfanalyst.com\/products\/nmtc-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}